Are Analysts Bearish Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) After Last Week?

May 16, 2018 - By reb123z

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) LogoInvestors sentiment decreased to 1.34 in Q4 2017. Its down 0.28, from 1.62 in 2017Q3. It dropped, as 53 investors sold Vertex Pharmaceuticals Incorporated shares while 160 reduced holdings. 72 funds opened positions while 213 raised stakes. 232.48 million shares or 0.46% more from 231.42 million shares in 2017Q3 were reported.
Cim Mangement accumulated 3,473 shares. Picton Mahoney Asset Mgmt accumulated 93,900 shares. 1832 Asset Mgmt Limited Partnership holds 981,100 shares. Rampart Mgmt Company Llc invested 0.18% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 4,850 were accumulated by Endurance Wealth. Jacobs Levy Equity Management has invested 0.52% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Bogle Management L P De stated it has 82,792 shares or 0.91% of all its holdings. 8,900 were reported by American Rech Management Co. Driehaus Capital Management Ltd Limited Liability Company reported 0.01% stake. Loring Wolcott & Coolidge Fiduciary Advsr Limited Liability Partnership Ma holds 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 820 shares. World Asset accumulated 0.11% or 22,398 shares. Jane Street Gru Ltd Company reported 5,816 shares or 0% of all its holdings. Captrust reported 0% stake. De Burlo Gru owns 17,900 shares for 0.54% of their portfolio. Dorsey Wright And Assoc, a California-based fund reported 14,779 shares.

Since December 11, 2017, it had 0 insider purchases, and 44 sales for $106.32 million activity. 8,969 shares valued at $1.52 million were sold by Arbuckle Stuart A on Wednesday, January 24. The insider Silva Paul M sold 9,883 shares worth $1.71M. 4,520 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $736,800 were sold by Sachdev Amit. Another trade for 23,905 shares valued at $3.61 million was made by LEIDEN JEFFREY M on Monday, February 12. Shares for $8.83 million were sold by ALTSHULER DAVID on Tuesday, January 16. Parini Michael also sold $6.49M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 18 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 18 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vertex Pharmaceuticals had 25 analyst reports since December 12, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Friday, January 5 by Bank of America. Credit Suisse maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday, February 13 with “Outperform” rating. The firm has “Buy” rating by Maxim Group given on Wednesday, January 31. On Monday, March 5 the stock rating was maintained by Maxim Group with “Buy”. Oppenheimer upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Thursday, February 1. Oppenheimer has “Buy” rating and $190.0 target. BMO Capital Markets maintained the shares of VRTX in report on Thursday, February 1 with “Buy” rating. The stock has “Buy” rating by Barclays Capital on Thursday, February 1. The firm has “Buy” rating by BMO Capital Markets given on Tuesday, January 2. RBC Capital Markets maintained it with “Buy” rating and $200.0 target in Wednesday, January 31 report. The rating was maintained by JMP Securities on Tuesday, December 12 with “Buy”. Below is a list of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) latest ratings and price target changes.

27/04/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $200 New Target: $207 Maintain
27/04/2018 Broker: Oppenheimer Rating: Buy New Target: $190.0000 Maintain
04/04/2018 Broker: RBC Capital Markets Rating: Buy New Target: $199.0000 Maintain
13/03/2018 Broker: Cowen & Co Rating: Buy New Target: $200.0 Maintain
05/03/2018 Broker: Maxim Group Old Rating: Buy New Rating: Buy Old Target: $195 New Target: $200 Maintain
23/02/2018 Broker: Argus Research Rating: Buy New Target: $194.0
13/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $200 New Target: $211 Maintain
13/02/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $195 New Target: $196 Maintain
02/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $198 New Target: $200 Maintain
01/02/2018 Broker: Oppenheimer Rating: Buy New Target: $190.0 Upgrade

The stock increased 0.40% or $0.62 during the last trading session, reaching $156.16. About 971,857 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 76.59% since May 16, 2017 and is uptrending. It has outperformed by 65.04% the S&P500.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $39.79 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 150.3 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Streetinsider.com which released: “Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies – RBC” on May 15, 2018, also Seekingalpha.com with their article: “Vertex Pharmaceuticals Heads Toward An Important Tipping Point” published on May 01, 2018, Fool.com published: “3 Top Biotech Stocks to Buy in May” on May 09, 2018. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Fool.com and their article: “Vertex Pharmaceuticals Takes a Detour Around the FDA’s Roadblock” published on April 30, 2018 as well as Globenewswire.com‘s news article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery …” with publication date: May 10, 2018.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


WP Twitter Auto Publish Powered By : XYZScripts.com